Currently, upon newly diagnosed SCLC and relapsed SCLC, the standard clinical practice of SCLC is the administration of various checkpoint inhibitors such as Atezolizumab (PD-L1) or Ipilimumab (CTLA-4), together with radiotherapy and platinum-based chemotherapy [2]. Here, CD274 is linked to small cell lung carcinoma.